Ondansetron
- Generic Name
- Ondansetron
- Brand Names
- Zofran, Zuplenz
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19N3O
- CAS Number
- 99614-02-5
- Unique Ingredient Identifier
- 4AF302ESOS
- Background
A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
...
- Indication
In the adult patient population:
i) orally administered ondansetron tablets and orally disintegrating tablets (ODT) are indicated for:
- the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including high dose (ie. greater than or equal to 50 mg/m2) cisplatin therapy, and radiotherapy, and
...
- Associated Conditions
- Chemotherapy-Induced Nausea and Vomiting, Cholestatic pruritus, Post Operative Nausea and Vomiting (PONV), Radiation-Induced Nausea and Vomiting, Uremic Pruritus, Severe Hyperemesis gravidarum
- Associated Therapies
- -
Postoperative Analgesia in Patients With Microvascular Decompression
- Conditions
- Interventions
- First Posted Date
- 2017-05-15
- Last Posted Date
- 2018-05-15
- Lead Sponsor
- Xiangya Hospital of Central South University
- Target Recruit Count
- 90
- Registration Number
- NCT03152955
- Locations
- 🇨🇳
Xiangya Hospital of Central South University, Changsha, Hunan, China
Comparison of IV Fluid Loading and Ondansetron in Reduction of PONV After LC
- Conditions
- Interventions
- First Posted Date
- 2017-05-05
- Last Posted Date
- 2019-04-04
- Lead Sponsor
- Siriraj Hospital
- Target Recruit Count
- 171
- Registration Number
- NCT03141645
- Locations
- 🇹🇭
Mingkwan Wongyingsinn, Bangkok, Thailand
Post-Operative Therapy for Nausea or Vomiting
- First Posted Date
- 2017-03-09
- Last Posted Date
- 2019-06-18
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 300
- Registration Number
- NCT03075163
- Locations
- 🇺🇸
UC Davis Health, Sacramento, California, United States
Triage Administration of Ondansetron for Gastroenteritis in Children
- First Posted Date
- 2017-02-14
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- St. Justine's Hospital
- Target Recruit Count
- 81
- Registration Number
- NCT03052361
- Locations
- 🇨🇦
CHU Sainte-Justine, Montreal, Quebec, Canada
Evaluating Pain Outcomes of Caudal vs Ilioinguinal Nerve Block in Children Undergoing Hernia Repair
- First Posted Date
- 2017-02-03
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- Alberta Children's Hospital
- Target Recruit Count
- 88
- Registration Number
- NCT03041948
- Locations
- 🇨🇦
Alberta Children's Hospital, Calgary, Alberta, Canada
🇨🇦Royal University Hospital/University of Saskatchewan, Saskatoon, Saskatchewan, Canada
Evaluating Pain Outcomes of Caudal vs Ilioinguinal Nerve Block in Children Undergoing Orchiopexy Repair
- Conditions
- Interventions
- First Posted Date
- 2017-02-03
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Alberta Children's Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT03041935
- Locations
- 🇨🇦
Alberta Children's Hospital, Calgary, Alberta, Canada
Quality of Recovery After Dexamethasone, Ondansetron or Placebo Intrathecal Morphine Administration
- Conditions
- Interventions
- First Posted Date
- 2017-01-30
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- Pontificia Universidade Catolica de Sao Paulo
- Target Recruit Count
- 135
- Registration Number
- NCT03035942
- Locations
- 🇧🇷
Santa Lucinda Hospital, Sorocaba, SP, Brazil
Neurobiological and Cognitive Changes Following Exposure to Either Sevoflurane- or Propofol-based Anesthesia in Children
- Conditions
- Interventions
- First Posted Date
- 2017-01-16
- Last Posted Date
- 2020-03-26
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 50
- Registration Number
- NCT03022240
- Locations
- 🇨🇦
University of Calgary, Calgary, Alberta, Canada
Therapeutic Efficacy of Ramosetron for Treatment of Established PONV After Laparoscopic Surgery
- First Posted Date
- 2017-01-11
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 80
- Registration Number
- NCT03017222
Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide
- Conditions
- Interventions
- First Posted Date
- 2016-12-13
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- Duke University
- Target Recruit Count
- 48
- Registration Number
- NCT02991456
- Locations
- 🇺🇸
The Preston Robert Tisch Brain Tumor Center at Duke, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.